Subscribe to our RSS feeds RSS | Login | Register  
 

 Promotion Articles

Docs rate Merck tops for ePromotion

Stephen McGuire March 31, 2008

Doctors rate Merck's ePromotion efforts as tops in the industry, according to pharmaceutical marketing data firm Verispan.
 

Sanofi-Aventis and Lilly in Cialis marketing pact

Ben Comer March 27, 2008

Sanofi-Aventis has teamed with Eli Lilly in a collaboration to market erectile-dysfunction drug Cialis (tadalafil) to US urologists.
 

TAP tapped by Shire for Lialda co-promote

Stephen McGuire March 27, 2008

Shire has entered a three-year deal with TAP Pharmaceutical to co-promote ulcerative colitis treatment, Shire's Lialda, in the US.
 

Lilly denies NY Times Zyprexa report

Stephen McGuire March 17, 2008

Eli Lilly has denied the assertions of a recent New York Times article alleging that incoming CEO John Lechleiter encouraged off-label promotion of the company's embattled schizophrenia treatment Zyprexa (olanzapine) in an e-mail he sent in 2003.
 

People news

March 13, 2008

Endo Pharmaceuticals announced that David Holveck has been named president, CEO and a director of the company, effective April 1, 2008.
 

Endo, Novartis begin Voltaren gel licensing deal

Stephen McGuire March 13, 2008

Endo Pharmaceuticals has entered into a licensing agreement with Novartis to obtain the exclusive US marketing rights for the prescription medicine Voltaren Gel (diclofenac sodium topical gel) 1%.
 

Shire hits the road with ulcerative colitis patient awareness program

Stephen McGuire March 10, 2008

Shire Pharmaceuticals is hitting "the road" as part of a new unbranded education campaign for patients with ulcerative colitis (UC), complete with live events in 10 cities.
 

People news

March 06, 2008

Publicis Healthcare Communications Group announced the appointment of Lyn Falconio to EVP, network navigator on the AstraZeneca account.
 

Allergan subpoenaed over Botox promotion materials

Stephen McGuire March 05, 2008

Allergan said it has received a subpoena for documents related to the promotion of its anti-wrinkle injection Botox.
 

FDA's off-label guidance harsh, but better than nothing, say legal experts

Matthew Arnold February 28, 2008

Sales reps could be effectively barred from circulating journal article reprints discussing off-label uses under FDA's draft guidance on "good reprint practices," and the agency considers the policy to be effective already, even in its draft form.